CO - Global Cord Blood Corporation

NYSE - Nasdaq Real Time Price. Currency in USD

2.9876

0.0000

(0.00%)

At close: 09:42AM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	2.2200
Open	2.2100
Bid	0.0000 x 1000
Ask	0.0000 x 1000
Day's Range	2.2200 - 3.3200
52 Week Range	2.0300 - 3.8500
Volume	0
Avg. Volume	0

Market Cap	400.084M
Beta (5Y Monthly)	-0.04
PE Ratio (TTM)	5.06
EPS (TTM)	0.5900
Earnings Date	Jul 03, 2023 - Jul 07, 2023
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	Jul 31, 2018
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Undervalued

30% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for CO

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

PR Newswire
GLOBAL CORD BLOOD CORPORATION ANNOUNCES FAILURE TO FILE INTERIM FINANCIALS
Global Cord Blood Corporation (NYSE: CO) (the "Company"), a provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services in China, announced that it received a notice (the "Notice") on April 3, 2023 from the New York Stock Exchange ("NYSE") with respect to its failure to timely file on Form 6-K its semi-annual financials for the six-month period ended September 30, 2022 (the "Interim Financials") as required by NYSE Listing Standard 20
Business Wire
Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands
HONG KONG, September 26, 2022--Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand Court of the Cayman Islands ("Grand Court") on September 22, 2022 (the "Order") appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant
Business Wire
The Grand Court of the Cayman Islands Granted Blue Ocean’s Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation
NEW YORK, September 23, 2022--Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE: CO), today announced the Grand Court of the Cayman Islands (the "Court") issued an order granting the appointment of joint provisional liquidators ("JPLs") for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22
PR Newswire
Global Cord Blood Corporation Files Annual Report on Form 20-F
Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The filed Form 20-F includes audited financial statements for the fiscal year ended March 31, 2022. The Form 20-F can be accessed by visiting the U.S. Securities and Exchang
PR Newswire
Global Cord Blood Corporation Obtained Injunction Order Against Blue Ocean in respect of Purported EGM
Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that an injunction order (the "Order") previously obtained by the Company on June 15, 2022 from the Grand Court of the Cayman Islands (the "Court") against Blue Ocean Structure Investment Company Limited ("Blue Ocean") was officially issued by the Court on July 6, 2022. The Orde
PR Newswire
Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022
Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal 2022, ended March 31, 2022.
PR Newswire
Global Cord Blood Corporation Announced Cellenkos Receives FDA Clearance of IND Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis
Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, is pleased to announce that Cellenkos, Inc. ("CLNK") recently announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application to initiate a Phase 1b, open-label study of CK0804 as an add on therapy to ruxolitinib in patients with myelof
Business Wire
Shareholders Led by Blue Ocean Announce Successful Results of Extraordinary General Meeting of Global Cord Blood Corporation
NEW YORK, June 16, 2022--Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") and shareholders representing over 75% of the outstanding shares of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE: CO) today announced the successful approval of all resolutions at the Global Cord Extraordinary General Meeting of Shareholders ("EGM") held today. 104,369,577 shares out of 121,551,075 total outstanding shares of Global Cord voted in the EGM, which represents 85.86 percent o
PR Newswire
Global Cord Blood Corporation Announces Purported EGM Is Not Validly Convened
Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, noticed that on June 3, 2022 Blue Ocean Structure Investment Company Limited (the "Petitioner") issued a notice which purported to convene an extraordinary general meeting of the Company ("Purported EGM") which is due to be held on June 16, 2022.
Business Wire
Shareholders of Global Cord Blood Corporation Are Reminded to Comply with the Rules of Conduct When Attending the Extraordinary General Meeting and Exercising Their Voting Rights
NEW YORK, June 15, 2022--Blue Ocean Structure Investment Company Ltd.,("Blue Ocean") together with shareholders representing no less than 75% of the outstanding shares of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE: CO) have called an Extraordinary General Meeting of Shareholders ("EGM" or the "Meeting") as allowed by the Company’s Articles. The EGM will be held at DLA Piper LLP (US), 1251 Avenue of the Americas, New York, NY 10020-1104, United States of America, on 16 J
Business Wire
Shareholders Led by Blue Ocean Call Extraordinary General Meeting of Global Cord Blood Corporation Shareholders to Terminate its Proposed Acquisition of Cellenkos, Inc. and Elect New Board
NEW YORK, June 03, 2022--Blue Ocean Structure Investment Company Ltd.,("Blue Ocean") announced today that shareholders representing no less than 75% of the outstanding shares of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE: CO), have called an Extraordinary General Meeting of Shareholders ("EGM") as allowed by the Company’s Articles. The EGM will be held at DLA Piper LLP (US), 1251 Avenue of the Americas, New York, NY 10020-1104, United States of America, on 16 June, 2022